A Study in Patients With Different Types of Advanced Cancer (Solid Tumors) to Test Different Doses of BI 907828 (Brigimadlin) in Combination With BI 754091 (Ezabenlimab) and BI 754111 or BI 907828 (Brigimadlin) in Combination With BI 754091 (Ezabenlimab)

Central Hospital of Northern Pest - Military Hospital, Budapest

UZ Leuven, Leuven

Linear Clinical Research, Nedlands

Memorial Sloan-Kettering Cancer Center, New York

NEXT Virginia, Fairfax

Hospital Clínico San Carlos, Madrid

University Cancer and Blood Center, Athens

INS Bergonie, Bordeaux

Universitätsklinikum Frankfurt, Frankfurt

Washington University School of Medicine, St Louis

CTR Leon Berard, Lyon

NEXT Oncology-Irving-69444, Irving

The University of Texas MD Anderson Cancer Center, Houston

NEXT Oncology-San Antonio-65273, San Antonio

Universitätsklinikum Ulm, Ulm

Sarcoma Oncology Center, Santa Monica

INS Gustave Roussy, Villejuif

National Cancer Centre Singapore, Singapore

Yale Cancer Center, New Haven

National Cancer Center Hospital, Tokyo, Chuo-ku

Universitair Medisch Centrum Groningen, Groningen

Hospital Universitari Vall D Hebron, Barcelona

The Royal Marsden Hospital, Chelsea, London